#USA #Camarillo #Biomanufacturing #Meissner #Automated Aliquoting System

Meissner Corporation Unveils the Automated Aliquoting System (AAS)

On October 19, 2026, Meissner Corporation presented their latest innovation, the Automated Aliquoting System (AAS). This advanced system is engineered to streamline the filling and transfer process of bulk cell culture media, buffers, and other process solutions into final single-use biocontainers, covering volumes from 1 to 20 liters. By introducing the AAS, Meissner targets the significant challenges in single-use biomanufacturing, particularly operator dependency.

Enhancing Consistency and Efficiency

The introduction of the AAS comes in response to the growing demand for efficiency within the biomanufacturing sector. The core benefit of the AAS lies in its ability to provide consistent fill outcomes, irrespective of operator skill or shift changes. This ensures that every batch produced meets the highest standards, which is crucial for maintaining the integrity of the manufacturing process.

One of the notable attributes of the AAS is its recipe-driven approach, minimizing variations and errors that typically arise from manual operations. By empowering teams to utilize pre-defined recipes, the system allows for faster campaign changeovers across different container formats and batch sizes, ultimately boosting productivity and reducing downtime.

Furthermore, real-time batch records are generated during the filling process. This feature not only enhances record-keeping accuracy but also supports regulatory compliance without the risks associated with manual transcription.

Compliance and Data Integrity

In today's highly regulated environment, compliance with standards such as 21 CFR Part 11 is non-negotiable. The AAS is designed to generate electronic records and auditable trails, ensuring data integrity and traceability throughout the filling process. This feature is paramount for biomanufacturers aiming to uphold stringent quality and safety standards while streamlining their workflows.

Teams can easily carry out review-by-exception workflows, which enhance the efficiency of quality control processes. The reduced reliance on direct human intervention in classified areas further fortifies contamination control strategies, making the entire manufacturing process safer and more reliable.

Supporting a Global Customer Base

Meissner Corporation is committed to advancing pharmaceutical and biopharmaceutical manufacturing through its innovative solutions. Their broad portfolio encompasses a variety of filtration media and single-use systems, coupled with an expanding array of automation platforms that cater to the specific needs of their clients.

With offices spanning multiple countries, Meissner is poised to provide comprehensive support throughout the lifecycle of manufacturing processes. Their expert team is ready to assist clients from the design stage to implementation and validation, fostering a collaborative approach that enhances operational efficiency.

As Meissner continues to evolve and innovate in the biomanufacturing landscape, the launch of the Automated Aliquoting System stands as a testament to their dedication to quality, efficiency, and regulatory compliance. For more information about the AAS and how it can transform your biomanufacturing process, visit Meissner's official website or contact their marketing department directly.

Conclusion

The Automated Aliquoting System is not just a product; it is a vital tool in the biomanufacturing process that guarantees consistent results and enhances efficiency. In an industry where precision and reliability are paramount, Meissner Corporation's AAS marks a significant leap forward, reinforcing their position as a leader in biopharmaceutical solutions.